A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 26 Aug 2015
At a glance
- Drugs Exenatide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DURATION-NEO-2
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 10 Jun 2017 Biomarkers information updated
- 22 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Mar 2014 Planned End Date changed from 1 Feb 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.